Explore more publications!
Africa News Ledger
Got News to Share?

Africa News Ledger: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Ledger.

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

February 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

Press releases published on January 20, 2026

Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue
Jan. 20, 2026

Cosmos Health Announces Accelerating Customer Growth, Improving Unit Economics and Robotic Expansion Supporting $40M in Additional Annual Revenue

Indeterminate GlobeNewswire
Koryx Copper Announces Closing of $46 Million Bought Deal Financing and Concurrent $5 Million Namibian Non-Brokered Private Placement
Jan. 20, 2026

Koryx Copper Announces Closing of $46 Million Bought Deal Financing and Concurrent $5 Million Namibian Non-Brokered Private Placement

Indeterminate GlobeNewswire
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
Jan. 20, 2026

BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026

Indeterminate GlobeNewswire
BrightInsight Strengthens Executive Leadership Team with Three Key Hires to Accelerate Global Growth and Innovation
Jan. 20, 2026

BrightInsight Strengthens Executive Leadership Team with Three Key Hires to Accelerate Global Growth and Innovation

Indeterminate GlobeNewswire
Latin Metals Provides Update on Partner-Funded Exploration, Cerro Bayo Gold–Silver Project, Argentina
Jan. 20, 2026

Latin Metals Provides Update on Partner-Funded Exploration, Cerro Bayo Gold–Silver Project, Argentina

Indeterminate GlobeNewswire
BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions
Jan. 20, 2026

BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions

Indeterminate GlobeNewswire
Rio Silver Initiates Process to Access High-Grade Silver Surface Mineralization and Enable Underground Access at Maria Norte
Jan. 20, 2026

Rio Silver Initiates Process to Access High-Grade Silver Surface Mineralization and Enable Underground Access at Maria Norte

Indeterminate GlobeNewswire
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
Jan. 20, 2026

Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome

Indeterminate GlobeNewswire
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
Jan. 20, 2026

RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center

Indeterminate GlobeNewswire
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
Jan. 20, 2026

Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Indeterminate GlobeNewswire
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
Jan. 20, 2026

LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29

Indeterminate GlobeNewswire
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) 
Jan. 20, 2026

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) 

Indeterminate GlobeNewswire
Erdene Provides Bayan Khundii Gold Mine Update
Jan. 20, 2026

Erdene Provides Bayan Khundii Gold Mine Update

Indeterminate GlobeNewswire
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
Jan. 20, 2026

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

Indeterminate GlobeNewswire
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
Jan. 20, 2026

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

Indeterminate GlobeNewswire
Aya Gold & Silver Achieves Financial Completion with EBRD for Zgounder Silver Mine Expansion
Jan. 20, 2026

Aya Gold & Silver Achieves Financial Completion with EBRD for Zgounder Silver Mine Expansion

Indeterminate GlobeNewswire
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
Jan. 20, 2026

NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing

Indeterminate GlobeNewswire
Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Jan. 20, 2026

Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Indeterminate GlobeNewswire
BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency
Jan. 20, 2026

BPGbio Receives FDA Orphan Drug Designation for BPM31510 for the Treatment of Primary CoQ10 Deficiency

Indeterminate GlobeNewswire
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
Jan. 20, 2026

Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions